Corrigendum to “Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity” [Bioorgan. Chem. 117 (2021) 105447]
Ling Li(Maryland Department of Health), Yinrong Wu(Southern Medical University), Chenglong Xu(Southern Medical University), Zichao Yang(Southern Medical University), Jingxuan Chen(East China University of Technology), Huiting Zhao(Jiangsu University), Jin Liu(Southern Medical University)
Cited by 0
Related Papers
Novel CRBN-Recruiting Proteolysis-Targeting Chimeras as Degraders of Stimulator of Interferon Genes with In Vivo Anti-Inflammatory Efficacy
|Journal of Medicinal Chemistry|2022|94
Mixed Lignan−Neolignans from <i>Tarenna attenuata</i>
|Journal of Natural Products|2007|74
Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity
|Bioorganic Chemistry|2021|40
Biosynthetic molecular imaging probe for tumor-targeted dual-modal fluorescence/magnetic resonance imaging
|Biomaterials|2020|39
<p>The Effect of Size, Dose, and Administration Route on Zein Nanoparticle Immunogenicity in BALB/c Mice</p>
|International Journal of Nanomedicine|2019|31